Positron raises $2M to expand PET-CT commercialization
Positron Corp. has raised $2 million to fund its commercial expansion of its new positron emission tomography CT (PET-CT) imaging system. This will include funds for product development, regulatory activities, pursuing new markets and expanding its clinical and service offerings.
The company has been a pioneer in cardiac PET imaging and is now focused on a new cost-effective, next generation PET-CT system it developed with Neusoft Medical Systems. The vendor said the new system is aimed at the rapidly expanding demand for advanced cardiac PET imaging solutions. Wider adoption of PET had been seen in the market in recent years and is accelerating. Cardiac imaging departments are adding PET systems because of the modality's enhanced diagnostic information compared to SPECT, including myocardial flow reserve information that can be used to show microvascular disease.
“We are encouraged by the continued support from investors, which reflects growing confidence in Positron’s strategy and long-term growth potential. An improved balance sheet positions the company to expand its market presence, increase system placements, and advance the next generation of our PET-CT technology,” explained Adel Abdullah, Positron's president, in a statement.
While focused on cardiac applications, Positron said it is expanding its offerings for oncology with its new PET-CT system for either shared service, or as a standalone system for either cardiology or oncology.
The company raised the capital in exchange for 1.3 million shares of the company’s stock.
